Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients

Phase 3 Completed 876 enrolled Boehringer Ingelheim Eli Lilly and Company · collab

RandomizedFactorialDouble-blindTreatment

Reduced factorial design study with 24 week randomized treatment of initial combination therapy with linagliptin and metformin in T2DM patients

Evaluation	Drug	Modality	Dose	Route
Subject	Linagliptin	Small molecule	2.5 mg	Oral
Subject	Linagliptin	Small molecule	5 mg	Oral
Subject	Metformin	Small molecule	500 mg	Oral
Subject	Metformin	Small molecule	1000 mg	Oral